Clinical Utility of Serum Interleukin-8 and Interferon-Alpha in Thyroid Diseases

Table 3

Significance of IL-8 levels in patients with thyroid diseases as compared to healthy individuals.

Subjects	Mean ± S.E (pg/ml)	Median	Minimum	Maximum	P value
Healthy individuals	3.15 ± 0.58	2.97	0.00	7.00
Total patients	231.67 ± 72.51				.001
Goitre	187.16 ± 93.88	8.41	0.00	1899.06	.002
Autoimmune disorders	185.30 ± 167.84	7.92	0.00	2700.00	.034
Graves’ disease	20.21 ± 10.93				.085
Hashimoto disorder	680.57 ± 673.14				.097
Thyroid Carcinoma	284.08 ± 118.97	69.35	0.00	3200.00	.001
Papillary carcinoma	116.34 ± 44.36				.006
Follicular carcinoma	514.13 ± 295.64				.030
Medullary carcinoma	828.96 ± 790.79				.456
Anaplastic carcinoma	27.17 ± 19.50				.003
Early stage (Stage I & II)	101.56 ± 53.89				.286
Advanced stage (Stage III & IV)	445.12 ± 214.30				<.001